Shares of iBio Inc. IBIO jumped 10.16% to $2.71 Tuesday, on what proved to be an all-around poor trading session for the ...

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the developme ...

Achievement strengthens iBio’s partnered cardiometabolic and obesity program while showcasing its proprietary AI-driven drug ...

Shares of iBio Inc. IBIO inched 0.41% higher to $2.46 Monday, on what proved to be an all-around mixed trading session for ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a ...

Bio (IBIO) announced the expansion of its cardiometabolic and obesity treatment development program by in-licensing a potentially ...

Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific ...

(RTTNews) - iBio, Inc. (IBIO), a preclinical stage biotechnology company, Thursday said it has in-licensed a long-acting anti-myostatin antibody, IBIO-600 from AstralBio, Inc. iBio has initiated a ...

The state's life sciences industry has seen job growth of 7.5% since 2019, 20 times that of the overall private sector growth ...

Shares of iBio, Inc. (NYSE:IBIO – Get Free Report) rose 2.5% during trading on Wednesday . The company traded as high as $2.44 and last traded at $2.42. Approximately 57,343 shares changed hands ...